Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: Evotec completes acquisition of Rigenerand: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
Acadia Healthcare Names R. David Kelly to Board of Directors
Acadia Healthcare Names R. David Kelly to Board of Directors


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that R. David Kelly has been appointed to serve as an independent director on the Company’s Board of Directors.


This press release

DGAP-News: Evotec SE reports results of Annual General Meeting 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: Evotec enters a drug discovery collaboration with Janssen: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec enters a drug discovery collaboration with Janssen
DGAP-News: Evotec enters a drug discovery collaboration with Janssen
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Humana Launches CenterWell Pharmacy and CenterWell Specialty Pharmacy
Humana Launches CenterWell Pharmacy and CenterWell Specialty Pharmacy


Humana Inc. (NYSE: HUM), a leading health and well-being company, has announced that Humana Pharmacy and Humana Specialty Pharmacy are now CenterWell Pharmacy and CenterWell Specialty Pharmacy

Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
Waters stellt hochauflösende Massenspektrometrie-Produkte und -Software zur Beschleunigung der Wirkstoffentwicklung vor
Waters stellt hochauflösende Massenspektrometrie-Produkte und -Software zur Beschleunigung der Wirkstoffentwicklung vor


ASMS 2022 – Die Waters Corporation (NYSE:WAT) hat heute auf der Jahreskonferenz der American Society for Mass Spectrometry 2022 (ASMS) neue Instrumente, Softwarelösungen und Produktverbesserungen

DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)
STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million

Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development
Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development


ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry

Humana Adds 14 States in Phase 2 of CenterWell Home Health Launch
Humana Adds 14 States in Phase 2 of CenterWell Home Health Launch


Humana Inc. (NYSE: HUM) has announced the addition of 14 states to the ongoing initiative to rebrand the home health division of Kindred at Home (KAH) as CenterWell Home Health. The announcement of

Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes
Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes


Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily

Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes
Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes


Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily

DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
DGAP-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD
DGAP-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022